A
Alok Tiwari
Researcher at University College London
Publications - 40
Citations - 2256
Alok Tiwari is an academic researcher from University College London. The author has contributed to research in topics: Blood vessel prosthesis & Endothelial stem cell. The author has an hindex of 19, co-authored 37 publications receiving 2142 citations. Previous affiliations of Alok Tiwari include Royal Free Hospital.
Papers
More filters
Journal ArticleDOI
Acute compartment syndromes
TL;DR: This review encompasses both limb and abdominal compartment syndrome, including aetiology, diagnosis, treatment and outcome.
Journal ArticleDOI
Improving the clinical patency of prosthetic vascular and coronary bypass grafts: the role of seeding and tissue engineering.
TL;DR: This review encompasses the developments in the two principal technologies used in developing hybrid coronary and peripheral vascular bypass grafts, that is, seeding and tissue engineering.
Journal ArticleDOI
Differential diagnosis, investigation, and current treatment of lower limb lymphedema
TL;DR: The common differential diagnosis in Western patients with lower limb swelling is secondary lymphedema, venous disease, lipedema, and adverse reaction to ipsilateral limb surgery.
Journal ArticleDOI
Anticoagulant and antiplatelet agents: their clinical and device application(s) together with usages to engineer surfaces.
Asmeret G. Kidane,Henryk J. Salacinski,Alok Tiwari,K. Richard Bruckdorfer,Alexander M. Seifalian +4 more
TL;DR: The current state of the art of antiplatelet and anticoagulant therapy is reviewed in light of its potential clinical efficacy and the usage of these agents more specifically heparin, heparan, hirudin, and coumarin in the development of more biocompatible scaffolds for tissue engineering is looked at.
Journal ArticleDOI
In vivo biostability of a poly(carbonate-urea)urethane graft.
Alexander M. Seifalian,Henryk J. Salacinski,Alok Tiwari,Alan Edwards,Staffan Bowald,George Hamilton +5 more
TL;DR: This compliant polyurethane vascular graft "MyoLink" retains its compliance post-implantation, whilst exhibiting only a minor hydrolysis of the amorphous segment, confirming its biostability in vivo up to 3 years.